Hemogenyx Pharmaceuticals (HEMO) RNS Announcements

Add to Alert list
Date Time Source Announcement
27 Feb 2018 04:40 PM
RNS
Second Price Monitoring Extn
27 Feb 2018 04:35 PM
RNS
Price Monitoring Extension
26 Feb 2018 02:17 PM
RNS
Stmnt re Share Price Movement
12 Feb 2018 07:00 AM
RNS
Director/PDMR Shareholding
07 Feb 2018 07:00 AM
RNS
Director/PDMR Shareholding
11 Jan 2018 07:00 AM
RNS
Hemogenyx Welcomes N.Y. Lt. Governor to its Labs
07 Dec 2017 12:16 PM
RNS
Result of AGM
07 Dec 2017 07:00 AM
RNS
AGM Statement
20 Nov 2017 07:00 AM
RNS
University of Oxford Collaboration
15 Nov 2017 07:00 AM
RNS
Directorate Change
14 Nov 2017 07:00 AM
RNS
Notice of AGM
13 Nov 2017 04:40 PM
RNS
Second Price Monitoring Extn
13 Nov 2017 04:35 PM
RNS
Price Monitoring Extension
13 Nov 2017 02:05 PM
RNS
Second Price Monitoring Extn
13 Nov 2017 02:00 PM
RNS
Price Monitoring Extension
13 Nov 2017 11:05 AM
RNS
Second Price Monitoring Extn
13 Nov 2017 11:00 AM
RNS
Price Monitoring Extension
13 Nov 2017 09:05 AM
RNS
Second Price Monitoring Extn
13 Nov 2017 09:00 AM
RNS
Price Monitoring Extension
13 Nov 2017 07:00 AM
RNS
Statement re Press Comment
30 Oct 2017 07:00 AM
RNS
LakePharma appointed for lead product development
11 Oct 2017 07:00 AM
RNS
Director/PDMR Shareholding
10 Oct 2017 07:00 AM
RNS
Director/PDMR Shareholding
05 Oct 2017 08:01 AM
RNS
Cornell University update
05 Oct 2017 08:00 AM
RNS
Admission & First Day of Dealings
04 Oct 2017 11:16 AM
RNS
Result of General Meeting
26 Sep 2017 07:00 AM
RNS
Investor presentations
25 Sep 2017 07:00 AM
RNS
Half-year Report
11 Sep 2017 07:00 AM
RNS
Proposed acquisition and Placing & Subscription
13 Apr 2017 03:30 PM
RNS
Final Results
30 Sep 2016 02:00 PM
RNS
Proposed acquisition of Lime Holdings Limited
05 Aug 2016 07:00 AM
RNS
Interim Report for the period ended 30 June 2016
29 Jun 2016 07:00 AM
RNS
Results of Annual General Meeting
01 Jun 2016 09:43 AM
RNS
Posting of Annual Report & Accounts
28 Apr 2016 07:00 AM
RNS
Final Results for period ended 31 December 2015
18 Feb 2016 10:33 AM
RNS
Change of Accounting Reference Date
30 Dec 2015 07:00 AM
RNS
Statement re possible acquisition
23 Dec 2015 12:48 PM
RNS
Suspension of trading
18 Dec 2015 11:07 AM
RNS
Appointment of Financial Advisor
07 Dec 2015 05:36 PM
RNS
Statement re: media speculation
27 Nov 2015 03:00 PM
RNS
Interim Report for the period ended 31 August 2015
25 Nov 2015 11:56 AM
RNS
Holding(s) in Company
17 Nov 2015 03:26 PM
RNS
Holding(s) in Company
17 Nov 2015 01:19 PM
RNS
Holding(s) in Company
16 Nov 2015 12:47 PM
RNS
Holding(s) in Company
16 Nov 2015 07:00 AM
RNS
Appointment of Broker
11 Nov 2015 05:15 PM
RNS
Holding(s) in Company
09 Nov 2015 07:00 AM
RNS
Placing of Shares & admission to Official List LSE

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

Hemogenyx Pharmaceuticals PLC is a preclinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma.

Hemo share price launched on LSE at 3p in 2017.

UK 100